• Global glomerulosclerosis in a mouse with type 2 diabetes. (Picrosirius red staining; original magnification ×100.)

  • 1.

    Ruggenenti P, et al.. Preventing microalbuminuria in type 2 diabetes. N Engl J Med 2004; 351:19411951.

  • 2.

    Yusuf S, et al.. Effects of an angiotensin-converting–enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000; 342:145153.

  • 3.

    de Zeeuw D, et al.. Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease for the BEACON trial investigators. N Engl J Med 2013; 369:24922503.

  • 4.

    Menne J, et al.. C-C motif-ligand 2 inhibition with emapticap pegol (NOX-E36) in type 2 diabetic patients with albuminuria. Nephrol Dial Transplant 2017; 32:307315.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 5.

    Wanner C, et al.. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 2016; 375:323334.

  • 6.

    Zinman B, et al.. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015; 373:21172128.

  • 7.

    Perkovic V, et al.. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy [published online ahead of print Apr 14, 2019]. N Engl J Med doi:10.1056/NEJMoa1811744.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 8.

    Groop P-H, et al.. Linagliptin and its effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: The randomized MARLINA-T2D trial. Diabetes, Obes Metab 2017; 19:16101619.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 9.

    Mann JFE, et al.. Liraglutide and renal outcomes in type 2 diabetes. N Engl J Med 2017; 377:839848.

  • 10.

    Van JAD, et al.. Insights into diabetic kidney disease using urinary proteomics and bioinformatics. J Am Soc Nephrol 2017; 28:10501061.

  • 11.

    Darshi M, et al.. Metabolomics in diabetic kidney disease: Unraveling the biochemistry of a silent killer. Am J Nephrol 2016; 44:92103.

  • 12.

    Verma S, McMurray JJV. SGLT2 inhibitors and mechanisms of cardiovascular benefit: A state-of-the-art review. Diabetologia 2018; 61:21082117.

Diabetic Kidney Disease What We Knew, What We Know, and What We Still Do Not Know

Lidia Anguiano Lidia Anguiano, PhD, and Hans-Joachim Anders, MD, are in the renal division of the Medizinische Klinik and Poliklinik IV, Klinikum der Universität München, LMU München, Germany.

Search for other papers by Lidia Anguiano in
Current site
Google Scholar
PubMed
Close
and
Hans-Joachim Anders Lidia Anguiano, PhD, and Hans-Joachim Anders, MD, are in the renal division of the Medizinische Klinik and Poliklinik IV, Klinikum der Universität München, LMU München, Germany.

Search for other papers by Hans-Joachim Anders in
Current site
Google Scholar
PubMed
Close
Restricted access
Save